Diflucan IV, oral — Competitive Intelligence Brief

Diflucan IV, oral (Diflucan IV, oral) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Triazole antifungal. Area: Infectious Disease.

phase 3 Triazole antifungal Lanosterol 14α-demethylase (CYP51) Infectious Disease Small molecule

Target snapshot

Diflucan IV, oral (Diflucan IV, oral) — Pfizer. Diflucan (fluconazole) inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Diflucan IV, oral TARGET	Diflucan IV, oral	Pfizer	phase 3	Triazole antifungal	Lanosterol 14α-demethylase (CYP51)
Vfend (voriconazole) tablet	Vfend (voriconazole) tablet	Seoul National University Hospital	marketed	Triazole antifungal	Cytochrome P450 14α-demethylase (CYP51)
Voriconazole high dose	Voriconazole high dose	Manjunath Prakash Pai	marketed	Triazole antifungal	Fungal cytochrome P450 lanosterol 14α-demethylase (CYP51)
Voriconazole clinical practice	Voriconazole clinical practice	Instituto de Investigación Hospital Universitario La Paz	marketed	Triazole antifungal	Fungal cytochrome P450 lanosterol 14α-demethylase (CYP51)
anidulafungin and voriconazole	anidulafungin and voriconazole	Pfizer	marketed	Echinocandin and triazole antifungal combination	β-1,3-glucan synthase (anidulafungin); fungal CYP51/lanosterol 14α-demethylase (voriconazole)
medium itraconazole tablet	medium itraconazole tablet	University of Maryland, Baltimore	marketed	Triazole antifungal	Fungal CYP51 (lanosterol 14α-demethylase)
Voriconazole low dose	Voriconazole low dose	Manjunath Prakash Pai	marketed	Triazole antifungal	Lanosterol 14α-demethylase (CYP51)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Triazole antifungal class)

1. University of Maryland, Baltimore · 3 drugs in this class
2. Manjunath Prakash Pai · 2 drugs in this class
3. Pfizer · 2 drugs in this class
4. Janssen Pharmaceutical K.K. · 1 drug in this class
5. Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
6. Merck Sharp & Dohme LLC · 1 drug in this class
7. Seoul National University Hospital · 1 drug in this class
8. University of California, San Francisco · 1 drug in this class
9. University of Minnesota · 1 drug in this class
10. Bayer · 1 drug in this class